SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 12, 2005
- -------------------------------------------------------------------------------
ENZON PHARMACEUTICALS, INC.
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-12957 2-2372868
- -------------------------------------------------------------------------------
(State or other jurisdiction (Commission file Number) (IRS Identification No.)
of incorporation)
685 Route 202/206, Bridgewater, New Jersey 08807
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (908) 541-8600
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[_] Written communication pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[_] Pre-commencement communication pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)
[_] Pre-commencement communication pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
On May 12, 2005 Enzon Pharmaceuticals, Inc. appointed Robert C. Salisbury to
Enzon's Board of Directors and Audit Committee. Enzon's Board of Directors has
also determined that Mr. Salisbury is an "audit committee financial expert," as
defined by the rules of the Securities Exchange Act of 1934. On May 16, 2005,
Enzon issued a press release announcing the appointment, which is attached to
this current report as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Description
99.1 Press Release dated May 16, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: May 16, 2005
By: /s/ Craig A. Tooman
---------------------------------
Craig A. Tooman
Executive Vice President,
Strategic Planning
and Corporate Communications
Exhibit 99.1
Enzon Announces the Appointment of New Member to Its Board Of Directors
BRIDGEWATER, N.J.--(BUSINESS WIRE)--May 16, 2005--Enzon
Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Robert C.
Salisbury has been appointed to the Company's Board of Directors and
Audit Committee. Enzon's Board of Directors has also determined that
Mr. Salisbury is an "audit committee financial expert," as defined by
the rules of the Securities Exchange Act of 1934.
In 1998, Mr. Salisbury retired from Pharmacia & Upjohn, Inc. where
he most recently served as Executive Vice President and Chief
Financial Officer. In this capacity, Mr. Salisbury was responsible for
all of the company's financial functions, as well as corporate
strategy, human resources, investor relations, and corporate
communications. Previously, Mr. Salisbury served as Executive Vice
President, Finance and Chief Financial Officer at The Upjohn Company,
where he played an integral role in planning, implementing, and
integrating the merger between Pharmacia and The Upjohn Company in
1995. Mr. Salisbury first joined The Upjohn Company in 1974 and over a
20-year career, he served in various management posts in finance and
strategic planning.
"Mr. Salisbury is a distinguished financial executive with more
than 20 years of senior management experience in the pharmaceutical
industry," said Jeffrey H. Buchalter, Enzon's chairman and chief
executive officer. "Bob's extensive financial expertise will be a
significant asset to our Board of Directors, as well as our audit
committee."
Mr. Salisbury also serves as a director of the biotechnology
company, Viragen, Inc. He received his Master of Business
Administration in 1972 and his Bachelor of Science in finance in 1965
from Florida State University.
About Enzon
Enzon Pharmaceuticals is a biopharmaceutical company dedicated to
the development and commercialization of therapeutics to treat
life-threatening diseases. The Company has developed or acquired a
number of marketed products, including PEG-INTRON(R), marketed by
Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and
DEPOCYT(R), marketed in North America by Enzon's specialized sales
force. Enzon's science-driven strategy includes an extensive drug
development program that leverages the Company's macromolecular
engineering technology platforms, including PEG modification and
single-chain antibody (SCA(R)) technologies. Internal research and
development efforts are complemented by strategic transactions that
provide access to additional marketed products and promising clinical
compounds. Further information about Enzon can be found on the
Company's web site at www.enzon.com.
All information in this press release is as of May 16, 2005 and
the Company undertakes no duty to update this information.
CONTACT: Enzon Pharmaceuticals, Inc.
Susan Mesco
Director, Investor Relations
908-541-8678